← Back
Xilio Therapeutics
XLO · listed on Nasdaq · worth $58.76 million
$8.03
+0.35% on Nov 4
No insider bought Xilio Therapeutics stock in the last year. They sold it 2 times, $5.7K in all.
Red dot = an insider sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
Reverse split 1-for-14 in Mar 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what XLO ever actually traded at. The drop is real, but those huge old numbers aren't.
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
3.4M shares
52% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders sold Xilio Therapeutics stock and none bought. None of the 2 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Christopher James Frankenfield, Chief Financial Officer.
Big investors
People and funds that reported owning 5% or more of Xilio Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateStempoint Capital LP9.5%Aug 14
All reports
Every insider trade and SEC report we hold for Xilio Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Jan 5SoldChristopher James FrankenfieldJan 5 · Traded Jan 2 · Chief Financial Officer7,030 @ $0.6432$4.5K
Jun 18, 2025BoughtJames Samuel ShannonJun 18, 2025 · Traded Jun 17, 2025 · Director+36%25,000 @ $0.6886$17.2K
Jun 18, 2025BoughtJames Samuel ShannonJun 18, 2025 · Traded Jun 16, 2025 · Director+100%45,000 @ $0.6860$30.9K
Jun 18, 2025BoughtRene RussoJun 18, 2025 · Traded Jun 16, 2025 · PRESIDENT AND CEO+13%36,289 @ $0.6801$24.7K
Analysts, earnings and news
Analysts' price target
$20.00 average
1 analyst
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 2 quarters above
Q2 '26−$0.33 a share+$0.26
Q3 '25−$1.54 a share−$1.12